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Abstract
Background: Emerging data implicate nicotinamide phosphoribosyl transferase (NAMPT) in the pathogenesis of
cancer and inflammation. NAMPT inhibitors have proven beneficial in inflammatory animal models of arthritis and
endotoxic shock as well as in autoimmune encephalitis. Given the role of inflammatory responses in spinal cord
injury (SCI), the effect of NAMPT inhibitors was examined in this setting.
Methods: We investigated the effects of the NAMPT inhibitor FK866 in an experimental compression model of SCI.
Results: Twenty-four hr following induction of SCI, a significant functional deficit accompanied widespread edema,
demyelination, neuron loss and a substantial increase in TNF-a, IL-1b, PAR, NAMPT, Bax, MPO activity, NF-B
activation, astrogliosis and microglial activation was observed. Meanwhile, the expression of neurotrophins BDNF,
GDNF, NT3 and anti-apoptotic Bcl-2 decreased significantly. Treatment with FK866 (10 mg/kg), the best known and
characterized NAMPT inhibitor, at 1 h and 6 h after SCI rescued motor function, preserved perilesional gray and
white matter, restored anti-apoptotic and neurotrophic factors, prevented the activation of neutrophils, microglia
and astrocytes and inhibited the elevation of NAMPT, PAR, TNF-a, IL-1b, Bax expression and NF-B activity.
We show for the first time that FK866, a specific inhibitor of NAMPT, administered after SCI, is capable of reducing
the secondary inflammatory injury and partly reduce permanent damage. We also show that NAMPT protein levels
are increased upon SCI in the perilesional area which can be corrected by administration of FK866.
Conclusions: Our findings suggest that the inflammatory component associated to SCI is the primary target of
these inhibitors.
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Background
Nicotinamide phosphoribosyl transferase (NAMPT) is
an enzyme that catalyzes the synthesis of nicotinamide
mononucleotide (NMN) from nicotinamide (NM) and
5’-phosphoribosyl-1’-pyrophosphate (PRPP), thus playing
an important role in the cyclic biosynthetic pathway of
nicotinamide adenine dinucleotide (NAD). As such, this
enzyme is central to cellular bioenergetics, and may
control indirectly a number of signalling pathways that
depend on NAD levels, such as Poly (ADP-ribose) poly-
merase (PARP) and sirtuin activation [1]. A secreted
form has been described, which is also known as visfatin
or Pre-B cell colony-enhancing factor (PBEF) [2].
Indeed, it has also been postulated that NAMPT
behaves as an adipokine secreted from visceral fat tis-
sues [3] or may have an important role in immune sys-
tem. For example, NAMPT has been originally
identified as an extracellular proinflammatory cytokine,
able to induce cellular expression of inflammatory cyto-
kines such as tumor necrosis factor (TNF)-a, interleukin
(IL)-1b and IL-6 and to promote pre-B cell colony for-
mation [4,5]. Lymphocytes, dendritic cells, monocytes
and macrophages express NAMPT when presented
inflammatory stimuli [6-8]. This suggests that NAMPT,
either via the “NAD salvage pathway” or by other
unknown mechanisms relating to its secreted form, may
modulate innate or acquired immune functions.
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Emerging data implicate PBEF/NAMPT/Visfatin in the
pathogenesis of a number of different human diseases,
in particular in the field of cancer and inflammation [3].
The link between NAMPT and inflammation is rapidly
strengthening. Indeed, visfatin levels have been found
elevated in the systemic circulation of patients suffering
from diseases with inflammatory components, such as
type 2 diabetes [9], acute pancreatitis [10], osteoarthritis
[11], sepsis [12], atherosclerosis [13] and psoriasis [14].
The search for novel antitumoral drugs has led to the
identification of two inhibitors of NAMPT, FK866 (also
known as APO866) and CHS828, which have now
entered Phase II clinical trials. Given the role of
NAMPT in inflammatory processes, an important ques-
tion is whether these agents may protect from inflam-
matory damage. While in vitro evidences would support
the use of these drugs in inflammatory processes
[12,15], in vivo evidence is limited. Indeed, it has been
shown that FK866 is able to reduce disease burden in
inflammatory animal models of arthritis and endotoxic
shock [15,16] as well as in experimental autoimmune
encephalitis [17]. These studies have highlighted that
NAMPT inhibitors exert their effects in a pleiotropic
manner, by reducing cytokine release, as well as offset-
ting PARP and sirtuin activation.
Spinal cord injury (SCI) is a highly debilitating
pathology [18]. Although innovative medical care has
improved patient outcome, advances in pharmacother-
apy for minimizing neuronal injury and promoting
regeneration are limited. The complex pathophysiology
of SCI may explain the difficulty in finding a suitable
therapy. The primary traumatic mechanical injury to
the SC causes the death of a number of neurons that
cannot be regenerated: neurons continue to die for
hours following traumatic SCI [19]. The events that
characterize this successive phase to mechanical injury
are called “secondary damage” characterized by cellu-
lar, molecular, and biochemical cascades. The presence
of a local inflammatory response maintains and ampli-
fies the secondary damage [20]. When SCI occurs,
microglia in parenchyma is activated and macrophages
in circulation get across blood-brain barrier (BBB) to
act as intrinsic spinal phagocytes. These cells release
different pro-inflammatory mediators such as proin-
flammatory cytokines [21] and reactive oxygen species
(ROS) and nitrogen species [22]. Nitric oxide (NO)
produced by inducible nitric oxide synthase (iNOS)
modulate the secondary inflammatory response follow-
ing traumatic SCI [23]. ROS and peroxynitrite also
cause DNA damage, which results in the activation of
the nuclear enzyme PARP, depletion of NAD+ and
ATP and ultimately cell death [24]. Therefore, recently
it has been demonstrated that SCI induced PARP
activation [25].
In the light of these evidences and given the high
therapeutic unmet need of SCI, we investigated the pos-
sible contribution of NAMPT in this condition. We now
show that pharmacological inhibition of NAMPT given
after the injury leads to a significant reduction of
inflammatory cytokines, a histological improvement of




Male Adult CD1 mice (25-30 g, Harlan, Milan, Italy)
were housed in a controlled environment. Animal care
was in compliance with Italian regulations on protection
of animals used for experimental and other scientific
purpose (DM 116192) as well as with the EEC regula-
tions (DL 116/92, application of the European Commu-
nities Council Directive 86/609/EEC). All efforts were
made to minimize animal suffering and the number of
animals used.
SCI
We used the clip compression model described by Rivlin
and Tator [26]. Mice were anesthetized using chloral
hydrate (400 mg/kg body weight). A longitudinal inci-
sion was made on the midline of the back, exposing the
paravertebral muscles. These muscles were dissected
away exposing T5-T8 vertebrae. The spinal cord was
exposed via a four-level T5-T8 laminectomy and SCI
was produced by extradural compression at T6-T7 level
using an aneurysm clip with a closing force of 24 g. In
all injured groups, the spinal cord was compressed for 1
min. Sham animals were only subjected to laminectomy.
Following surgery, 1.0 cc of saline was administered sub-
cutaneously in order to replace the blood volume lost
during the surgery. During recovery from anesthesia, the
mice were placed on a warm heating pad and covered
with a warm towel. The mice were individually housed
in a temperature-controlled room at 27°C for a survival
period of 20 days. Food and water were provided to the
mice ad libitum. During this time period, the animals’
bladders were manually voided twice a day until the
mice were able to regain normal bladder function.
Experimental groups and treatments
Mice were randomly allocated into the following groups:
(i) sham + vehicle group. Mice were subjected to lami-
nectomy but the aneurysm clip was not applied, and
treated intraperitoneally with vehicle (N = 30). (ii) Sham
+ FK866 group. Identical to sham + vehicle group
except for intraperitoneal administration of FK866 (10
mg/kg) 1 h and 6 h after laminectomy (N = 30). (iii)
SCI + vehicle group. Mice were subjected to SCI and
were administered vehicle at 1 h and 6 h after SCI (N =
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30). (iv) SCI + FK866 group. Mice were subjected to SCI
and administered FK866 (10 mg/kg, intraperitoneally) at
1 h and 6 h after SCI (N = 30).
Timing of administration of FK866 was similar to that
proposed for methylprednisolone at high concentrations
(the current therapy available for traumatic SCI). FK866
were synthesized as reported [27]. The dose of FK866
used here was based on previous in vivo studies [15-17].
Alongside, all experiments were also performed with an
analogue of FK866, named GPP78, and data were super-
imposable to those obtained with FK866 (data not shown).
In a separate set of experiments to investigate the
motor score, additional animals (10 animals/each group)
were observed until 20 days after SCI. FK866 (10 mg/
kg) was administered 1 h and 6 h after SCI and daily
until day 19.
Tissue processing
At the end of the experimental period (24 hrs), animals
were deeply anesthetized with sodium pentobarbital and
then perfused transcardially with cold phosphate-buffered
saline (PBS, 0.1 M) followed by 4% paraformaldehyde in
0.1 M PBS, pH 7.4. SC tissues were removed under magni-
fied vision. Tissue segments containing the lesion (1 cm
on each side of the lesion) were paraffin embedded, cut
into longitudinal sections for posterior area of SC, and
processed for different immunohistochemical procedures.
Different tissues were also collected for Golgi-Cox
staining, which highlights neurons and processes
For immunoblotting analysis, mice (N = 10) were anaes-
thetized and exsanguinated via cardiac puncture. SCs
were dissected, and cleaned from meninges and nerve
roots. One centimeter of the cord centered at the injury
site was homogenized for preparing cytosolic and
nuclear extracts.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of poly-
morphonuclear leukocyte (PMN) accumulation, was
determined in SC tissues as previously described [28].
MPO activity was expressed in units/mg protein.
Measurement of TNF-a and IL-1b
SC tissues, collected at 24 hrs after SCI, were homoge-
nized in PBS containing 2 mmol/L of phenyl-methyl sul-
fonyl fluoride and tissue TNF-a and IL-1b levels were
evaluated by using a colorimetric commercial kit DuoSet
ELISA Development System (R&D Systems, Milan, Italy).
Immunohistochemical localization of Bax, Bcl-2, GFAP,
CD11-b, BDNF, GDNF, NT-3, PAR, and NAMPT
Sections (8 μm) were prepared from paraffin embedded
tissues. After deparaffinization, endogenous peroxidase
was quenched with 0.3% hydrogen peroxide in 60%
methanol for 30 minutes. The sections were permeabi-
lized with 0.1% Triton X-100 in PBS for 20 minutes.
Sections were incubated overnight with anti-Bax (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), or
anti-Bcl-2 (1:500, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-GFAP (1:500, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-CD11-b (1:500; AbD Sero-
tec, Raleigh, NC, USA), anti-BDNF (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-GDNF
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-NT3 (1:500, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-PAR (10 μg/ml; Merck Millipore,
Billerica, MA, USA), and NAMPT (10 μg/ml; Novus
Biologicals, Littleton, CO, USA). Sections were incu-
bated with secondary antibody. Specific labeling was
detected with a biotin-conjugated goat anti-rabbit IgG
and avidin-biotin peroxidase complex (Vector Lab. Inc.,
Burlingame, CA, USA). Immunocytochemistry photo-
graphs (n = 5 photos from each samples collected from
all mice in each experimental group) were assessed by
densitometry as previously described [29,30] by using
Optilab (Graftek, France) software on a Macintosh per-
sonal computer (CPU G3-266; Apple, Inc., Cupertino,
CA, USA).
Golgi-Cox staining
The tissues were fixed in 10% buffered formalin, and
placed on a layer of glass wool in a large volume of
Golgi-Cox solution and incubated at 37°C. After two
months of incubation, the tissue samples were washed,
dehydrated, cleared, wax impregnated and ultimately
embedded in molten paraffin wax. 50 μ-thick sections
were cut with the help of rotary microtome. The sec-
tions were collected in warm water and then mounted
on albumenised slides. The slides were kept in oven at
50°C for half an hour. The paraffin wax was removed by
immersing the slides in xylene. The slides were passed
through descending grades of alcohol and ultimately
dipped in distilled water. Blackening was done by pla-
cing the sections in 5% ammonia solution for one hour
and subsequently washed thoroughly in distilled water.
The tissue sections were dehydrated, cleared and
mounted.
Light microscopy
Section 5 μm-thick sections were deparaffinized with
xylene, stained with Haematoxylin/Eosin (H&E), with
Luxol Fast Blue with cresyl violet (Klüver and Barrera
stain) counterstaining (used to assess demyelination)
and studied using light microscopy (Dialux 22 Leitz,
Milan Italy). Damaged neurons were counted and the
histopathologic changes of the gray matter were scored
on a 6-point scale [31]: 0, no lesion observed, 1, gray
matter contained 1 to 5 eosinophilic neurons; 2, gray
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matter contained 5 to 10 eosinophilic neurons; 3, gray
matter contained more than 10 eosinophilic neurons; 4,
small infarction (less than one third of the gray matter
area); 5, moderate infarction; (one third to one half of
the gray matter area); 6, large infarction (more than half
of the gray matter area). The scores from all the sec-
tions from each spinal cord were averaged to give a final
score for an individual mice.
Terminal Deoxynucleotidyltransferase-Mediated UTP End
Labeling (TUNEL) Assay
TUNEL assay was conducted by using a TUNEL detec-
tion kit according to the manufacturer’s instruction
(Apotag, HRP kit DBA, Milan, Italy), as previously
reported [32]. The signals were visualized with
diaminobenzidine.
Preparation of spinal cord extracts and Western blot
analysis for phospho-NF-B p65 (serine 536), NF-B p65,
Bax and Bcl-2
Cytosolic and nuclear extracts were prepared as pre-
viously described [33] with slight modifications. The fil-
ters were blocked with 5% non-fat dried milk
(AppliChem GmbH, Germany) in PBS (PM) for 40 min-
utes at room temperature (RT) and subsequently probed
with specific Abs phospho-NFB p65 (serine 536) (Cell
Signaling, 1:1,000), or anti-Bax (1:500; Santa Cruz Bio-
technology, Santa Cruz, CA, U.S.A.), or anti-Bcl-2
(1:500; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.
A.), or anti-NFB p65 (1:1,000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, U.S.A.) in PM with 0.1% Tween-20
(Sigma-Aldrich, Milan, Italy) (PMT) at 4°C, overnight.
Membranes were incubated with peroxidase-conjugated
bovine anti-mouse IgG secondary antibody or peroxi-
dase-conjugated goat anti-rabbit IgG (1:2,000, Jackson
ImmunoResearch, West Grove, PA, USA) for 1 h at RT.
To ascertain that blots were loaded with equal amounts
of protein lysates, they were also incubated in the pre-
sence of the Abs against b-actin and lamin A/C
(1:10,000 Sigma-Aldrich, Milan, Italy). The relative
expression of the protein bands of phospho NFB (75
kDa), NFB p65 (65 kDa), Bax (approximately 23 kDa),
Bcl-2 (approximately 29 kDa) was quantified by densito-
metric scanning of the X-ray films with Imaging Densit-
ometer (GS-700, Bio-Rad Laboratories, Milan, Italy) and
a computer program (Molecular Analyst, IBM, Milan,
Italy).
Grading of motor disturbance
The motor function of mice subjected to compression
trauma was assessed once a day for 20 days after injury.
Recovery from motor disturbance was graded using the
Basso Mouse Scale (BMS) open-field score [34], since
the BMS has been shown to be a valid locomotor rating
scale for mice. The evaluations were made by two blind
observers for all analyzed groups. Briefly, the BMS is a
nine-point scale that provides a gross indication of loco-
motor ability and determines the phases of locomotor
recovery and features of locomotion. The BMS scale
ranges from 0 (indicating complete paralysis) to 9 (indi-
cating normal hindlimb function), rating locomotion on
aspects of hindlimb function such as weight support,
stepping ability, coordination, and toe clearance. The
BMS score was determined for ten mice in each group.
Materials
All compounds, except for FK866 and GPP78, were
obtained from Sigma-Aldrich (Milan, Italy). FK866 was
synthesized in house as described previously and was
over 99% pure [35]. All chemicals were of the highest
commercial grade available. All stock solutions were
prepared in non-pyrogenic saline (0.9% NaCl; Baxter,
Italy, UK).
Statistical evaluation
All values in the figures and text are expressed as mean
± standard error of the mean (SEM) of N observations.
For the in vivo studies N represents the number of ani-
mals studied. In the experiments involving histology or
immunohistochemistry, the figures shown are represen-
tative of at least 3 experiments performed on different
experimental days. The results were analyzed by one-
way ANOVA followed by a Bonferroni post-hoc test for
multiple comparisons. A p-value of less than 0.05 was
considered significant. BMS scale data were analyzed by
the Mann-Whitney test and considered significant when
p-value was < 0.05
Results and discussion
FK866 and GPP78 treatments reduce the severity of
spinal cord trauma
The severity of the trauma at the level of the perile-
sional area, assessed by the presence of edema as well as
alteration of the white matter and infiltration of leuko-
cytes, was evaluated 24 h after injury by hematoxylin/
eosin (H&E) staining. Significant damage was observed
in the spinal cord tissue collected from SCI (Figure 1b)
when compared with sham-operated mice (Figure 1a).
Protection against the SCI was observed in FK866-trea-
ted mice (Figure 1c). Moreover, to evaluate the severity
of the trauma we also investigated the alteration in mye-
lination. In sham-treated mice, as expected, myelin
appeared normal (Figure 2a). On the contrary, a signifi-
cant alteration was detected in the spinal cord tissues
collected at 24 hours after SCI (Figure 2b). Treatment
with FK866 (Figure 2c) significantly reduced the demye-
lination associated with SCI. The histological score was
evaluated by an independent observer and confirmed
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these findings (Figure 1e). In order to evaluate if histolo-
gical damage to the spinal cord was associated with a
loss of motor function, the BMS hind limb locomotor
rating scale score was evaluated. Mice subject to SCI
had significant deficits in movement (Figure 1f). Treat-
ment of animals with FK866 (Figure 1f) significantly
ameliorated the functional deficits induced by SCI. To
confirm these effects, we took advantage of a recently
synthesized analogue of FK866, named GPP78 [35].
Indeed, GPP78 displayed the same effects in histological
score and similar improvements in the motor activity of
SCI animals (Figures 1d, e, f).
FK866 modulates cytokines expression and neutrophil
infiltration after SCI
As our aim was to understand the mechanisms by which
NAMPT inhibitors exert this effect, we decided to con-
centrate solely on the most established of the two phar-
macological tools, FK866. To test whether FK866
modulates the inflammatory process through the regula-
tion of secretion of pro-inflammatory cytokines, we ana-
lyzed spinal cord tissue levels of TNF-a and IL-1b. A
substantial increase in TNF-a and IL-1b production was
found in spinal cord samples collected from SCI mice 24
h after SCI (Figure 3a and 3b respectively). Spinal cord
levels of TNF-a and IL-1b were significantly attenuated
by the administration of FK866 (Figure 3a). The histolo-
gical pattern of SCI seemed to be correlated with the
influx of leukocytes into the spinal cord. Therefore, we
investigated the effect of the treatments on the infiltra-
tion of neutrophils by measuring myeloperoxidase
(MPO), a lysosomal protein stored in azurophilic gran-
ules of the neutrophil (Figure 3c). MPO activity was sig-
nificantly elevated in the spinal cord at 24 h after injury
in mice subjected to SCI when compared with Sham-
operated mice (Figure 3c). In FK866-treated mice, the
activity of this peroxidase enzyme was significantly atte-
nuated (Figure 3c) in comparison to that observed in SCI.
Effect of FK866 on phosphorylation of p65 on Ser536 and
nuclear NF-B p65
By Western blot analysis, we evaluated the phosphoryla-
tion of Ser536 on the NF-B subunit p65 and nuclear
NF-B p65 to investigate the cellular mechanisms by
which treatments may attenuate the development of
SCI. SCI caused a significant increase in the phosphory-
lation of NF-B p65 on Ser536 at 24 h after the injury
Figure 1 Effects of FK866 treatment on histological alterations
of the spinal cord tissue 24 h after injury and motor function.
Significant damage to the spinal cord in mice subjected to SCI, at
the perilesional area, was apparent, as evidenced by the presence of
edema as well as alteration of the white matter 24 h after injury (b,
b1). Notably, an important protection from SCI-associated damage
was observed in the tissue samples collected from FK866 (c) treated
mice. GPP78 (d) displayed the same effects of FK866 in histological
score (e) and similar improvements in the motor activity (f). The
histological score (e) was made by an independent observer. The
degree of motor disturbance was assessed every day until 20 days
after SCI by BMS criteria (f). Treatments with FK866 enhanced the
recovery after SCI. This figure is representative of at least 3
experiments performed on different experimental days. Data are
means ± s.e. means of 10 mice for each group. *p < 0.01 vs. Sham.
°p < 0.01 vs SCI + vehicle.
Figure 2 Effects of FK866 treatment on myelin structure
alteration. Myelin structure was observed by Luxol fast blue
staining. At 24 h after the injury in SCI operated mice (b) a loss of
myelin was observed. In contrast in FK866 (c) treated mice myelin
degradation was attenuated. No significant alterations was observed
in sections obtained by sham groups (a). Moreover Weigert’s and
Oil Red staining is highly specific for degenerating myelin and for
myelin that has been ingested by macrophages. At 24 h after injury,
in SCI mice group was observed a greater density of Oil Red
staining as a marker for myelin destruction (b1) when compared
with control mice (a1). In contrast in FK866 (c1) treated mice myelin
degradation was attenuated. In order in the spinal cord tissue
collected from SCI mice, was observed the alteration of morphology
of neurons when compared with sham-operated mice (b2). A
protection against alteration of neuron’s morphology was observed
in mice group treated with FK866 (c2). This figure is representative
of at least 3 experiments performed on different experimental days.
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(Figure 4a and a1); treatment with FK866 prevented the
activation of NF-B (Figure 4a and a1). In addition, the
translocation of NF-Bp65 was also significantly
increased at 24 h after SCI compared with the sham-
operated mice (Figure 4b and b1). FK866 treatment sig-
nificantly reduced the levels of nuclear NF-B p65 pro-
tein as shown (Figure 4b and b1).
Instead, IB-a expression did not seem to be affected
by FK866 treatment at 24 h after the injury (data not
shown).
Effect of FK866 on NAMPT and PAR formation
Nicotinamide phosphoribosyl transferase activity has
been shown to be essential for maintaining adequate
intracellular NAD levels, influencing biological responses
such as cell survival and inflammation. We then evalu-
ated NAMPT presence with immunohistochemistry
staining. We reveled a positive staining in the spinal
cord tissues from mice subjected to SCI (Figure 5b, b1,
see densitometric analysis).
FK866 decreased the degree of positive staining for
NAMPT in the spinal cord from mice subjected to SCI
(Figure 5c). Moreover, immunohistochemistry for PAR,
as an indicator of in vivo PARP activation, revealed the
occurrence of positive staining for PAR localized in
nuclei of Schwann cells in the white and gray matter of
the spinal cord tissues from mice subjected to SCI (Fig-
ure 5e). FK866 treatment reduced the degree of positive
staining for PAR (Figure 5f) in the spinal cord.
Figure 3 Effects of FK866 on TNF-a and IL-1b release and on
MPO activity. A substantial increase in TNF-a (a) and IL-1b (b)
production was found in spinal cord tissue collected from SCI mice
at 24 h. Spinal cord levels of TNF-a and IL-1b were significantly
attenuated by the FK866. Moreover, MPO activity in spinal cord of
untreated SCI-operated mice was significantly increased at 24 h
after the damage in comparison to sham mice (c). Treatment with
FK866 significantly reduced the SCI-induced increase in MPO
activity. Data are means ± S.E.M of 10 mice for each group. *p <
0.01 vs sham, °p < 0.01 versus SCI + vehicle.
Figure 4 Effects of FK866 treatment on NF-B p65 activation.
By Western blot analysis, we evaluated the phosphorylation of
Ser536 on the NF-B subunit p65 and nuclear NF-B p65 to
investigate the cellular mechanisms by which treatments may
attenuate the development of SCI. SCI caused a significant increase
in the phosphorylation of NF-B p65 on Ser536 at 24 h after the
injury (a, a1); instead the treatment with FK866 prevented
significantly the activation of NF-B (a, a1). Moreover, traslocation
of NF-B p65 subunit in the nuclear fractions of the spinal cord
tissue were also significant increased at 24 h after SCI compared
with the sham-operated mice (b, b1). The levels of NF-B p65
protein were significantly reduced in the nuclear fractions of the
spinal cord tissues from animals that had received FK866 treatment
as shown in (b, b1). Immunoblotting in a, b are representative of
one spinal cord of five analyzed. The results in a1 and b1 are
expressed as mean ± S.E.M from five blots, *p < 0.01 vs sham, °p <
0.01 versus SCI + vehicle.
Figure 5 Effects of FK866 on NAMPT and PAR formation.
NAMPT and PAR formation was evaluated by immunohistochemical
analysis in the spinal cord section at 24 h after SCI. Spinal cord
section obtained from SCI animals demonstrated positive staining
for NAMPT in the white and gray matter (b, see the particular b1).
FK866 treatment reduced the degree for positive staining for
NAMPT in the spinal cord tissue (c). Moreover,
immunoistrochemistry for PAR revealed the occurrence of positive
staining for PAR in mice subject to SCI (e). FK866 treatment reduced
the degree for positive staining for PAR in the spinal cord tissue (f).
This figure is representative of at least 3 experiments performed on
different experimental days.
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Effect of FK866 on apoptosis in spinal cord after injury
To test whether the tissue damage was associated with
the induction of apoptosis, we evaluated at 24 h after
injury, the possible changes in apoptotic proteins (Bax
and Bcl-2) and the DNA fragmentation (TUNEL-like
staining).
Spinal cord tissue was taken at 24 h after SCI in order
to determine the immunohistological staining for Bax
and Bcl-2. Spinal cord sections from sham-operated
mice did not stain for Bax (Figure 6b, see densitometric
analysis 7e) whereas spinal cord sections obtained from
SCI mice (Figure 6c) exhibited a strong staining for Bax.
Treatment with FK866 (Figure 6d) decreased the degree
of positive staining for Bax in the spinal cord from mice
subjected to SCI.
In addition, spinal cord from sham-operated mice
demonstrated positive staining for Bcl-2 (Figure 7b)
while in SCI mice the staining for Bcl-2 was significantly
reduced (Figure 7c). FK866 (Figure 7d and 7e) treat-
ments restored the levels of this anti-apoptotic protein.
Similar results were obtained by western blot analysis.
No apoptotic cells were detected in the spinal cord
from sham-operated mice (Figure 8a). At 24 h after the
trauma, tissues from SCI mice demonstrated a marked
appearance of dark brown apoptotic cells and intercellu-
lar apoptotic fragments (Figure 8b). In contrast, tissues
obtained from mice treated with FK866 demonstrated
no apoptotic cells or fragments (Figure 8c and densito-
metric analysis).
Effect of FK866 on neurotrophic factors
To test whether FK866 modulates the inflammatory process
through regulation of neutrophic factors, we have examined
BDNF, GDNF and NT-3 levels in the perilesioned zone
both by immunohistochemistry. In the spinal cord tissues
collected at 24 h after the trauma, neurotrophic factors
expression levels were significantly reduced (Figure 9b, b1
and b2) in comparison to sham animals (Figure 9a, a1 and
a2). The treatment with FK866 (Figure 9c, c1, c2, and densi-
tometric analysis) significantly restored the levels of the
three neurotrophic factors up to that of uninjured mice.
Figure 6 Effects of FK866 on Bax expression. By western blot
and immunohistochemical analysis Bax levels were evaluated. Spinal
cord obtained from SCI-operated mice exhibited appreciably
increased Bax levels (a, a1 and c). FK866 (a, a1 and d) treatment
prevented the SCI-induced Bax expression. The relative expression
of the protein bands was standardized for densitometric analysis to
b-actin levels, reported in panel a, a1 and are expressed as mean ±
S.E.M from n = 5/6 spinal cord for each group. **p < 0.001 vs sham,
°°p < 0.001 vs SCI + vehicle.
Figure 7 Effects of FK866 on Bcl-2 expression. Moreover, a basal
level of Bcl-2 expression was detected in spinal cord from sham-
operated mice (a, a1 and b). Twenty-four hours after SCI, Bcl-2
expression was significantly reduced in spinal cord from SCI mice
(a, a1 and c). Treatment with FK866 (a, a1 and d) significantly
reduced the SCI-induced inhibition of Bcl-2 expression. The relative
expression of the protein bands was standardized for densitometric
analysis to b-actin levels, reported in panel a, a1 and are expressed
as mean ± S.E.M from n = 5/6 spinal cord for each group. *p < 0.01
vs sham, °°p < 0.001 vs SCI + vehicle.
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FK866 treatment reduces astrocyte and microglial
activation after SCI
Analysis was performed to elucidate the nature of cells
targeting by FK866. Spinal cord sections revealed
increased astrogliosis (GFAP + cells) in the perilesional
area after SCI (Figure 10b). On the contrary, a signifi-
cant number of non-GFAP positive cells were found in
the spinal cord from FK866-treated mice (Figure 10c).
Moreover, microglial cells were activated following SCI
as shown by increased CD11b-positive staining (Figure
10e). Expression of CD11b were attenuated by FK866
(Figure 10f, and densitometric analysis).
Conclusions
SCI can result in severe disability, and it is at present a
disease with a high therapeutic unmet need. The patho-
physiology of SCI can be divided in two separate distinct
phases: a primary injury elicited by the compression that
determines a patient’s prognosis and a secondary phase
which can exacerbate damage and limit restorative pro-
cesses, and therefore, contribute to overall morbidity
and mortality. Unambiguously, inflammatory response
following SCI contributes substantially to these second-
ary devastating effects. SCI-induced inflammation can
lead to further reduction in functional recovery because
of the development of scar tissue, as well as necrosis or
apoptosis of neurons and myelin forming oligodendro-
cytes [36].
In the present manuscript, we have investigated the
effect of the inhibition of an enzyme involved in NAD
metabolism, NAMPT, in SCI recovery. NAMPT exists
in two major forms, an intracellular one which has been
implicated directly in NAD homeostasis, and an extra-
cellular one, which is also named visfatin or PBEF [3].
Whether visfatin exerts its functions via modulating
NAD homeostasis is at present unclear, and a number
of other mechanisms have been proposed [37]; [38].
Furthermore, it cannot be ruled out that extracellular
NMN, the product of NAMPT, may have biological
functions. What is beyond doubt is that the extracellular
form of visfatin displays plasma increases in a number
of human inflammatory diseases.
Figure 8 Effects of FK866 on TUNEL-like staining in the
perilesional spinal cord tissue. At 24 h after the trauma, SCI mice
demonstrated a marked appearance of dark brown apoptotic cells
and intercellular apoptotic fragments (b). In contrast, tissues
obtained from mice treated with FK866 (c) no revealed apoptotic
cells or fragments. The number of TUNEL positive cells/high-power
field was counted in 5 to 10 fields for each coded slide. The count
of TUNEL cells per field was made by an independent observer. This
figure is representative of at least three experiments performed on
different experimental days. wm, white matter; gm, gray matter.
Values shown are mean ± S.E. mean of 10 mice for each group. *p
< 0.01 vs sham, °p < 0.01 vs SCI + vehicle.
Figure 9 Effects of FK866 on neurotrophins expression. Spinal
cord sections were processed at 24 h after SCI to determine the
levels for BDNF, GDNF and NT3 by immunohistochemical analysis. A
basal level of BDNF (a), GDNF (a1) and NT3 (a2) were detected in
the spinal cord from Sham-operated animals, whereas BDNF, GDNF
and NT3 levels were substantially reduced in SCI mice (b, b1, b2
respectively). FK866 (c, c1, c2 respectively) treatment prevented
the SCI-induced BDNF, GDNF and NT3 reduction. In panel d
densitometric analysis is reported. *p < 0.01 vs sham, °p < 0.01 vs
SCI + vehicle.
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We now show that NAMPT protein levels are
increased upon SCI in the peri-lesional area. This could
be due to the invasion of activated immune cells with
upregulated NAMPT expression [15] into the injured
spinal tissue. More importantly, we show for the first
time that NAMPT inhibition corrects elevated NAMPT
levels and ablates various inflammatory aspects of SCI-
associated secondary damage by targeting neutrophils,
macrophages, microglia and astrocytes, thereby leading
to a significant recovery of the motor performance of
injured animals.
Neutrophils are the first inflammatory cells to arrive at
the site of injury and are implicated in the modulation
of the secondary injury by release of reactive mediators
that damage endothelial cells and increase vascular per-
meability thereby exaggerating immune cell invasion to
the spinal cord leading to further damage [39]. Neutro-
phils infiltration, as measured by MPO activity was sig-
nificantly increased 24 h post trauma in spinal cord. In
FK866-treated animals, SCI-evoked elevated MPO level
was profoundly decreased and was accompanied by an
overall attenuation of inflammatory mediators and
motor function in mice.
Microglia and macrophages dominate the innate
immune response elicited by SCI and sustain the sec-
ondary damage in animal models of SCI [20] as macro-
phage activation and their cytokine release, notably
TNF-a and IL-1b, contribute to axonal demyelination
[40] and cell death [41]. Twenty-four h after traumatic
SCI, spinal content of the proinflammatory TNF-a and
IL-1b as well as CD11b positive cells displayed a sub-
stantial rise, while NAMPT inhibition by administration
of FK866 prevented the elevation of inflammatory mar-
kers. These findings paralleled the reversal by FK866 of
SCI-induced myelin degradation in spinal cord tissues as
verified by less myelin phagocytosis by macrophages in
Oil Red staining and less degenerating myelin in Luxol
fast blue staining. Moreover, in spinal cord sections
from injured-mice a dramatic astrogliosis denoted by
increased immunoreactivity of GFAP was observed. As
reactive astrocytes gives rise to an astroglial scar that
acts as a physical and/or chemical barrier to axonal
regeneration [42], its inhibition achieved by administra-
tion of FK866 is beneficial as was associated with more
intact white matter in histologic evaluation.
Apoptosis is another component of secondary injury
that can be triggered by a variety of insults including
cytokines, inflammatory injury and free radical damage.
Apoptosis in oligodendrocytes contributes to post-SCI
demyelination while apoptosis in neurons contributes to
cell loss [43,44]. In our study, apoptosis was evident in
both white and gray matter of injured spinal cord as evi-
denced by TUNEL positive cells and augmented tissue
Bax/Bcl-2 ratio. Interestingly in FK866-treated mice, no
apoptosis was detected, pro-apoptotic Bax significantly
decreased and anti-apoptotic Bcl-2 restored. These
observations were accompanied by the complete replen-
ishment of the neurotrophic factors BDNF, GDNF and
NT-3 as well as amelioration of neuron morphology in
perilesional spinal cord sections from mice receiving
FK866.
The beneficial properties of FK866 observed herein
would be in accord with recent reports indicating that
NAMPT inhibitors can ameliorate animal model symp-
tomatology of inflammatory diseases such as arthritis,
endotoxic shock and autoimmune encephalitis [15-17].
While the mechanism by which this class of drugs act
as anti-tumoral agents is thought to involve energy
deprivation [36], how FK866 should reduce inflamma-
tion is less straightforward. It has been recently shown
that a reduction of PARP and/or SIRT activity might in
part explain this phenomenon [17]. Indeed, this would
also be conceivable in SCI. PARP is a ubiquitous, chro-
matin-bound enzyme abundantly present in the nuclei
of numerous cell types [24](Szabó and Dawson, 1998).
Continuous or excessive activation of PARP produces
extended chains of ADP-ribose on nuclear proteins and
results in a substantial depletion of intracellular NAD+
and subsequently, adenosine triphosphate (ATP), leading
to cellular dysfunction and ultimately, cell death [45].
Consistent with our observation of a drastic rise in PAR
level, an indicator of PARP activation, 24 h following
SCI it has been demonstrated that SCI induces PARP
Figure 10 FK866 treatment reduces astrocyte and microglial
activation after SCI. Spinal cord sections revealed increased
astrogliosis (GFAP + cells) in the perilesional area after SCI (b). On
the contrary, a significant number of non-GFAP positive cells were
found in the spinal cord from FK866 (c) treated mice. Moreover,
microglial cells were activated following SCI as shown by increased
CD11b-positive staining (e). Expression of CD11b was attenuated by
FK866 (f) treatment. In panel g densitometric analysis is reported. *p
< 0.01 vs sham, °p < 0.01 vs SCI + vehicle.
Esposito et al. Journal of Neuroinflammation 2012, 9:66
http://www.jneuroinflammation.com/content/9/1/66
Page 9 of 11
activation [25] and that pharmacologic or genetic abla-
tion of PARP activity can reduce the degree of tissue
injury associated with spinal cord trauma [46]. Of note,
treatment with FK866 blunted the SCI-evoked PARP
activation indicating PARP as a potential signaling path-
way targeted by NAMPT inhibitors to elicit their neuro-
protection. SIRTs constitute another group of NAD-
dependent enzymes with divergent roles in neuronal
survival. SIRT1 elicits anti-apoptotic effects while
SIRT2, 3 and 6 have been shown to promote cell death
[47]. Specifically, SIRT2 is reportedly increased upon
damage to the spinal cord in rat following a proteomic
approach, while its pharmacological or genetic inhibition
protects against neurotoxicity in models of Parkinson’s
disease [48]. Therefore, it is plausible that NAD deple-
tion following administration of NAMPT inhibitors
decreases SIRT2 deacetylase activity and confers protec-
tion against deleterious stimuli in SCI. Of importance,
recent evidence also suggests that cell survival promot-
ing properties of SIRT1 might be mediated by a non-
catalytic mechanism and, hence, can be preserved in
presence of NAMPT inhibitors.
While the processes downstream of NAD depletion
have not been evaluated in the present manuscript, we
have observed that (i) inflammatory cytokines (eg. TNF-
a and IL-1b) are increased upon SCI and are significantly
reduced by NAMPT inhibition; (ii) NF-B expression
was also significantly increased upon SCI and normalized
by NAMPT inhibition and (iii) that neutrophil infiltration
and reactive gliosis, two hallmarks of the inflammatory
process which takes place in the injured spinal cord, were
significantly reduced by FK866 treatment. These data,
taken together, would suggest that the inflammatory
component of the injury is the primary target of these
inhibitors. FK866 could (also) alleviate SCI by inhibiting
TNF-a secretion by macrophages and microglia, thereby
reducing inflammation and thus preventing the damage.
This study suggests that FK866, a specific inhibitor of
NAMPT, administered after SCI, is capable of reducing
the secondary injury and partly reduce permanent
damage. The specificity of the effect is supported by the
fact that another inhibitor of NAMPT, termed GPP78,
elicits the same effects. Both drugs have been adminis-
tered after the trauma was elicited, in a setting that
mimics the clinical situation, and therefore our results
may have clinical implications.
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